About The Author

Editorial & Columns

FY24 Review: Intellectual Capital of Top Indian Pharmaceutical Companies

October 28, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Pay Gap in Indian Pharmaceutical Industry: Remuneration of Managerial Personnel vis-à-vis Employees

October 23, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Employment Dynamics in Indian Pharmaceutical Industry

October 16, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Potpourri

Obituary: Ratan Naval Tata

October 10, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Sustainable Finance in India: Gaining Traction

October 9, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Dividend Policy dynamics of Pharmaceutical Companies in India

October 4, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Indian Pharmaceutical Companies: Investment in R&D for “Jai Anusandhan”

September 25, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Forex Rate Risk: Measurement and Mitigation by Pharmaceutical Companies in India

September 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Skin in the Game: Decrease in Promoter Holding of Pharmaceutical Companies in India

September 4, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Board Characteristics of Pharmaceutical Companies in India

August 28, 2024 | Dr. Anil Kumar Angrish | No Comments |

More